The affect of influence of genes' polymorphisms CYP2C9 and VKORC1ON the safety of the therapy by warfarin
Автор: Zotova I.V., Nikitin A.G., Fattakhova E.N., Brovkin A.N., Khodyrev D.S., Lavrikova E.Y., Isaeva M.Y., Kosukhina A.S., Nosikov V.V., Zateyshchikov D.A.
Журнал: Клиническая практика @clinpractice
Рубрика: Оригинальные исследования
Статья в выпуске: 4 (16), 2013 года.
Бесплатный доступ
To study the distribution of alleles and genotypes of polymorphic markers of genes CYP2C9 and VKORC1 of Russian patients who live in Moscow, and in order to assess the influence of genetic factors on warfarin therapy 400 patients have been genotyped. The dosage of warfarin which is required for achievement of INR target values has been different among owners of different geno- types of polymorphic markers of genes CYP2C9. Meanwhile the highest average dose has been required for genotype *1/*1 and the lowest – for owners of alleles *2 and *3. For polymorphism G(- 1639)A of the gene VKORC1 the dosage of warfarin which is required for achievement of the INR target values, has been different among owners of different genotypes. The highest average dose has been required for genotype GG, and the lowest – for genotype AA. The results will allow to work out more accurate algorithm of choosing of the initial dose of warfarin depending on the genotypes of polymorphic markers of genes CYP2C9 and VKORC1.
Warfarin, polymorphic marker, individual sensitivity, pharmacogenetics
Короткий адрес: https://sciup.org/14338471
IDR: 14338471
